Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00927758 · ClinicalTrials.gov registry record · Phase 2

Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair

A Phase 2 study, sponsored by Sandoz.

Completed
Registry status
Phase 2
Development phase
105
Enrollment target

NCT00927758: Completed Phase 2 study, sponsored by Sandoz.

NCT00927758 is a Phase 2 study that has completed, run by Sandoz. The registered enrollment target is 105 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (21% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00927758, a Phase 2 study, has completed, sponsored by Sandoz.

COMPLETED
Registry status
Phase 2
Development phase
105 participants
Enrollment target

Study Summary

To examine the post-dose changes in exhaled Nitric Oxide (eNO) following treatment with inhaled Advair in subjects with chronic but stable asthma as defined in Global Initiative for Asthma (GINA) guidelines.

Primary Outcome

Percentage change in eNO was reported following treatment with inhaled Advair in subjects with chronic but stable asthma as defined in Global Initiative for Asthma (GINA) guidelines. eNO was calculated 3 times every day in a treatment cycle for 7 days. The maximum value of all 3 collected value were collected for each seven days of the individual treatment cycle. Out of the maximum values, the minimum was taken and used for calculating the percentage change from baseline.

Interventions

  • DRUG fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg

Trial Details

FieldValue
Enrollment Target 105 participants
Start Date 2009-06
Est. Completion 2009-12
Phase Phase 2
Sandoz

29 total trials

What the finished NCT00927758 record still lists

NCT00927758 is an interventional study that assigns participants to a tested intervention. The registered 105 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (21% lower).

The record links to 0 conditions, and to 1 intervention - of which fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg is the first listed.

NCT00927758 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00927758 about?

NCT00927758 is a clinical study titled "Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair". To examine the post-dose changes in exhaled Nitric Oxide (eNO) following treatment with inhaled Advair in subjects with chronic but stable asthma as defined in Global Initiative for Asthma (GINA) guidelines.

What is the current status of trial NCT00927758?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2009-06. Estimated completion is 2009-12.

What interventions are being tested in trial NCT00927758?

The interventions under investigation include: fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg (DRUG).

Who is sponsoring clinical trial NCT00927758?

This trial is sponsored by Sandoz, which has 29 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00927758's enrollment target sits among peer trials

105 650th of 2000 higher than 1,341 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03372317 · 105 participants

    Tau PET in Imaging and Cognition: Healthy Adults From 55-90

  • NCT04253964 · 105 participants · Phase 2

    Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

  • NCT04742452 · 105 participants · NA

    Comparison of Partial Rotator Cuff Repair vs. Superior Capsular Reconstruction for Irreparable Rotator Cuff Tears

  • NCT04875429 · 105 participants · NA

    Zenith® Fenestrated+ Clinical Study

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00927758, the US trial registry maintained by the National Library of Medicine. NCT00927758 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.